azathioprine (group I) and 49 age-matched patients with RA (group II), were studied to detect potential early markers of malignancy. Chest x-rays were similar in both groups. One patient in group I had a positive PAP smear and was subsequently found to have uterine carcinoma. Alpha-fetoprotein was positive in one patient in group I and none in group II. CEA was negative in all patients in group I, but positive in seven in group II. On chromosomal analysis group I showed a greater frequency of breakage. Group I showed lower serum folates and a highly significant number of megaloblastic features in marrow aspirates.
In group I seven tumours, three being malignant, occurred while taking azathioprine, and in group II six tumours, one malignant, were identified (p=017).
The apparent increased risk of malignancy previously suggested by others warrants further studies with larger populations and over a continuous longer period. Clinically, both groups were comparable as to grip strength, extra-articular manifestations and latex titre (table 2). They differed significantly in the joint count, with group II having a greater number of active joints (16 2 vs 11 3), and ESR, with group II having a lower ESR (51-3 vs 23 3). There were no marked differences in fertility, hormone treatment and history of cigarette smoking between the groups.
Both groups were comparable in terms of SGOT, alkaline phosphatase and protein electrophoresis results. The groups did not differ with respect to iron studies, haemoglobin and platelet, neutrophil and lymphocyte counts. The total white blood cell count was significantly lower in the azathioprine treated group (table 3) . Chest x-rays were similar in both groups. Inflammatory and fibrotic abnormalities were seen in 15 patients in group I and nine patients in group II. There were no suspicious lesions seen in either group. Mammography showed a comparable number of benign lesions, that is, fibrosis, generalised calcifications and/or dysplasia. No masses or signs of malignancy were seen except for one suspicious lesion in a woman in group I and three in group II. These women are being followed carefully and, thus far, show no evidence of malignancy.
Cervical smears (Papanicolaou) on all women were negative except for one patient in group I who subsequently was found to have adenocarcinoma of the uterus on curettage. Urine cytology was abnormal in four patients in group I and one patient in group lI, showing dyskaryotic changes. Those patients demonstrating abnormal urine cytology have been followed and none has shown development of urinary tract neoplasms.
Alpha-fetoprotein testing was positive in one patient in group I, with no evidence of associated malignancy. All 's,3 244;22but lesions were located in the genitourinary tract, a ained a serious common site for neoplastic change in the elderly case reports of female, and the benign lesions were found in the skin, n azathioprine liver, breast, bowel and uterus. There was one other cytotox-malignant neoplasm identified in control group 11, a quency of acute diffuse histiocytic lymphoma. Previously reported redominantly in prevalence rates of malignancy in RA have been either comparable to non-rheumatoid groups,1"' or associated with unexpectedly low (0-6 ( ).'26 The finding of three es when used in malignancies among 36 azathioprine treated patients management of as compared with one among the 49 controls is not e reported inci-statistically significant (p=0-1728 (table 4) .
Originally claimed to be a marker of bowel carcinoma, the CEA has now proven to be much less specific. None of the patients in the azathioprinetreated group had increased levels of CEA. Of interest, is the fact that seven of the control group had significant levels without evidence of any neoplasms. This finding of raised CEA levels in seropositive RA has been previously reported.222 223 Alpha-fetoprotein is another oncofetal antigen previously reported to be a potential marker for hepatic carcinoma.4 We detected this antigen in only one patient in group I, who proved to have no evidence of an associated malignancy. All patients in group II were negative for alpha-fetoprotein.
The problem of therapy with azathioprine in RA and the increasing incidence of neoplastic disease resulting from such treatment is a serious consideration, but to date no registry has been organised to gather and analyse such cases in a similar manner to that performed for organ transplant malignancies.
Without such an organisation, meaningful statistics and conclusions will inevitably be delayed. We conclude that the apparent increased risk, as demonstrated in this study, warrants further studies with larger populations and over a continuous longer period.
in rheumatoid arthritis. 
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